Rogan Sent Trump Info on Ibogaine for Addiction Treatment

Joe Rogan Shared Psychedelic Research with Donald Trump

Podcast host Joe Rogan revealed he sent information about ibogaine, a psychedelic drug, to former President Donald Trump. Rogan shared this during a discussion about potential medical reforms for psychedelic treatments.

He stated that these experimental treatments show life-changing potential for people with severe mental illness and depression. Rogan specifically mentioned the opioid crisis, highlighting the significant number of people struggling with addiction.

Ibogaine Shows Promise for Opioid Addiction

According to Rogan, ibogaine has demonstrated remarkable effectiveness in treating opioid addiction. He cited statistics suggesting that over 80% of individuals become free of addiction after a single dose.

This success rate reportedly rises to over 90% with two doses. This information was shared with Trump as part of a broader conversation about accelerating access to new medical research.

Trump’s Alleged Response to Ibogaine Information

Rogan recounted that after sending the information, he received a text message response from Trump. The former President allegedly replied, “Sounds great. Do you want FDA approval?

Let’s do it.” This exchange, as described by Rogan, suggests a potential openness from Trump’s administration towards exploring such treatments. The context was presented as part of an announcement about historic reforms aimed at speeding up access to psychedelic-based medical research and treatments.

The Science Behind Ibogaine and Addiction

Ibogaine is a psychoactive alkaloid derived from the root bark of the Tabernanthe iboga shrub. It has been studied for its potential to interrupt addiction cycles, particularly for opioids.

Unlike many traditional addiction treatments that manage withdrawal symptoms, ibogaine is believed to address the underlying neurological changes associated with substance dependence. Research, though still developing, suggests it might reset brain chemistry disrupted by long-term drug use.

Challenges and Future of Psychedelic Treatments

Despite promising early results, the use of ibogaine and other psychedelics for medical purposes faces significant hurdles. These include regulatory challenges, the need for more extensive clinical trials, and concerns about potential side effects.

The U.S. Food and Drug Administration (FDA) has strict protocols for approving new drugs, requiring rigorous testing for safety and efficacy. However, there is growing interest in the therapeutic potential of psychedelics, with some research moving toward FDA-approved clinical trials.

Broader Implications for Mental Health and Addiction

The conversation highlights a growing movement to explore alternative and potentially more effective treatments for mental health conditions and addiction. For years, the opioid crisis has devastated communities, and traditional methods have not been enough for everyone.

The idea that a single or double dose of a substance could offer such high success rates is a compelling prospect for millions. This potential shift could lead to new government policies and increased funding for research into psychedelic-assisted therapies.

What to Watch Next

The ongoing debate and research into psychedelic treatments will continue to evolve. Future developments will depend on further scientific study, clinical trial outcomes, and regulatory decisions.

The potential for policy changes regarding access to these substances for medical use remains a key area to monitor. Public and political interest, as evidenced by Rogan’s interaction, suggests this topic will remain in the spotlight.

Source: Joe Rogan says he sent Trump information on ibogaine (YouTube)